The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Tbf I think your right sandy as most of those 20 clients he said were pharma based which is research led, which means they are exempt from fda clia approval!! We absolutely do need clia for accreditation to do human tests as that will be classed as high complexity!! My thinking was clia first but you probably right which is better for us as once certificates are stamped it can take months for the fda to send them back for final verification for actual lab usage
Some monster trades sneaked in today roughly 600k pounds worth an not moved the share price an inch?? Must be buys as surely they'd crash the price otherwise!!
Hopefully satago is about to go fully live with Lloyds an sage!! Interesting times lay ahead
We've done two previous 200 patient studies to perfect our hycead chemical array system from harvesting ctcs via parsortix with the last one with an auc-roc of 95% which is classed as clinically excellent!! The only difference from the one we're waiting for is its blinded as far as I can see!! So triaging patients with malignant or benign plevic masses to appropriate surgeons and then retrospectively analysing lumps to confirm if the mass was indeed benign or malignant
There are many codes already established for pulmonary scans etc all with overlapping or broad terminology cpt 78579 78580 78582 seems to focus on xenon tho so I'm sure these could be piggybacked onto!! However cpt31615 could be used in conjunction!! Basically it's not a new field of medicine just a different type of machine used for imaging so codes an tools already exist
Cpt-76376 and Cpt-3766 should cover it as broadly speaking it's just a lung imaging scan which already is catered for, albeit ours is just a more enhanced image!! It's upto to consultant to read and interpret any image they see ie choose what device they use
https://se.copernicus.org/articles/13/793/2022/
Hope this link works great background to previous disko survey campaigns
Who knows it's very possible, however dundas bfs is due add also thunderstone/disko survey results September/October time and Finland is kicking around in the background still!! Dundas and disko are the real drivers with this one tho!! Disko could be very interesting
The potential market for a Bolt on mri scanner is in the multi billions!! Top end scanners each costing over 1million dollars each is the first port of call when any consultant wants to diagnose you!! If your machine costs so much money why wouldn't you stump up a couple of extra 100grand and be able to diagnose pulmonary issues to individual bronchial tubes as opposed to:
doc I feel breathless
OK blow into this bottle
You seem breathless
I know, why?
I don't know mate my scanner is plop an doesn't show me nothing!!
Only for stupid technicalities we'd already be raking in orders it's a total no brainer
Excellent so with this order we're 1m down this year excluding grupo? With further orders it basically makes the grupo contract net profit with hopefully Indian orders to add to the balance sheet!! So cash positive h3 finally
With all points raised by the crl comprehensively looked at by market specialists and the original fda approval being at 90% personally this is a stonewall pass for me now all risk has been mitigated manufacturing technicalities sorted out ill be adding to my holding any time it dips from now till September and leaving it in
The last rns re satago stated that the letter of intent has been signed with commercial agreements being finalised in the coming months. So absolutely nothing has changed except your patience!! Its a screaming buy right now with the slight discount not a sell at the bottom like right now
Richard Hullihen CEO of Polarean CEO said: "We are happy that the FDA has accepted our resubmission and look forward to resuming the review process with them in the expanded context of our response!! This part has me worried a bit, only with the fda not us but expanded suggests over and above from last time so new info to digest and.......
Does the class 2 reinforce the theory that the fda never gave us a proper look last time an just issued the crl to buy time? Hopefully this time around they wont be as inundated with c19 eua and can give us a fair crack of the whip
Many more rns actually as the license areas are huge!! No need for any dilution as we're already fully funded for production via epcf sinosteel agreement!! The major costs of developing a mine are actually the infrastructure but as we're in a mining district already all of that is already in place!! With our own processing plant and toll treatment capability we'll be able to service multiple areas simultaneously with only the one capital expenditure, negating any single asset risk!! Truly bottom quartile of the aisc percentage curve!!